JAMA Network
What The Study Did: Researchers describe the antispike IgG antibody response to the SARS-CoV-2 BNT162b2 messenger RNA (mRNA) vaccine (BioNTech-Pfizer) in patients with cancer compared with healthy controls about four months after the second vaccine dose.
Authors: Salomon M. Stemmer, M.D., of the Rabin Medical Center, Beilinson Hospital in Petah Tikva, Israel, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2021.4390)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
